← stocks-llm New chat Find companies like NVS →

NOVARTIS AG (NVS)

Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.

View SEC filings Filings archive → Website Yahoo Finance Find companies like NVS → Ask about NVS →

What NOVARTIS AG does

Novartis is a Swiss multinational pharmaceutical and biotechnology company that discovers, develops, manufactures, and markets prescription medicines, biologics, and gene therapies. The company operates across multiple therapeutic areas including oncology, immunology, cardiovascular, respiratory, neuroscience, and gene therapy, serving patients globally. Novartis focuses on addressing serious unmet medical needs, particularly in rare genetic diseases and life-threatening conditions. The company combines traditional small-molecule pharmaceuticals with advanced modalities including monoclonal antibodies, oligonucleotide conjugates, and gene therapies.

Themes: Rare genetic neuromuscular diseases, Oligonucleotide therapeutics / RNA interference, Gene therapy, Oncology, Immunology and inflammation, Monoclonal antibodies, Disease-modifying treatments

Fundamentals

Dividend: yield +3.0%; pays a dividend.

Ask why NVS looks like this →

Key risks (from latest filing)

["R&D execution risk: Advanced pipeline programs (del-brax, del-desiran, del-zota) in late-stage development could fail to meet efficacy or safety endpoints in Phase III trials or regulatory approval, materially impacting future revenue growth.","Regulatory and market approval uncertainty: Therapies for rare neuromuscular diseases face unpredictable regulatory pathways; delays or rejections could defer or eliminate revenue from orphan-designated programs.","Patent expiration and generic competition: Loss of exclusivity on key marketed drugs as patents expire could significantly erode revenue streams and profitability across therapeutic portfolios."]

See NVS's biggest risks from its latest 10-Q →

Insider activity (SEC Form 4)

No open-market insider purchases or sales recorded in the last 90 days.

Most recent open-market transaction: 2020-06-30. As of 2026-07-21.

View full insider trading history → View SEC Form 3/4/5 filings

Ask about NVS's insider activity →

Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.

Competitors & peers

AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.

Not quite? Describe exactly what you want →

NOVARTIS AG is found in…

NVS shows up in…

Frequently asked questions

What does NOVARTIS AG (NVS) do?

Novartis is a Swiss multinational pharmaceutical and biotechnology company that discovers, develops, manufactures, and markets prescription medicines, biologics, and gene therapies. The company operates across multiple therapeutic areas including oncology, immunology, cardiovascular, respiratory, neuroscience, and gene therapy, serving patients globally. Novartis focuses on addressing serious unmet medical needs, particularly in rare genetic diseases and life-threatening conditions.

Does NVS pay a dividend?

Yes — NOVARTIS AG (NVS) pays a dividend, with an indicated yield of about 2.96% (Finnhub, as of 2026-07-21). Informational only — not financial advice.

Who are NOVARTIS AG's (NVS) competitors?

Notable peers of NOVARTIS AG (NVS) include Roche, Merck, Pfizer, Johnson & Johnson and Bristol Myers Squibb. This peer set is informational only — not financial advice.

Where does stocks-llm's data on NVS come from?

Fundamentals and prices come from Finnhub, as of 2026-07-21; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.

Fundamentals: Finnhub, as of 2026-07-21. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-20.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.